Vesugen. The Lys-Glu-Asp tripeptide bioregulator targeting the vascular wall.
A 20mg lyophilized vial of Vesugen (L-lysyl-L-glutamyl-L-aspartic acid), a short peptide bioregulator from the Khavinson program, researched for its influence on the vascular wall, endothelial cells, and gene expression in cardiovascular aging models.
Ten of the 20mg vial at 40% off run $360, which is $36 a vial and $1.80 per milligram. The ladder is 2 vials 5%, 3+ vials 10%, 5-pack 25%, 10-pack 40%, off the single-vial price, applied in the cart. Any mixed box of ten vials across sizes or products takes 25% off.
One tripeptide. One target tissue. One vial.
Vesugen is a three-amino-acid peptide (lysine-glutamic acid-aspartic acid) developed at the St. Petersburg Institute of Bioregulation and Gerontology as a short-peptide bioregulator directed at vascular tissue. Where the wider bioregulator family covers many organ systems, Vesugen is the member studied specifically in the context of blood vessels and the endothelium.
What Vesugen Brings
Vesugen is a synthetic tripeptide composed of L-lysine, L-glutamic acid, and L-aspartic acid (Lys-Glu-Asp). It belongs to the class of short peptide bioregulators developed by Professor Vladimir Khavinson and colleagues, a research program built around isolating the minimal active peptide sequences responsible for tissue-specific regulatory effects. Within that framework, Vesugen is the sequence assigned to the vascular system, which is why its research base concerns blood vessels and endothelial tissue.
The proposed mechanism of the short peptide bioregulators is distinctive. Rather than acting primarily on cell-surface receptors, this class is studied for its ability to enter the cell, reach the nucleus, and interact directly with DNA to influence gene expression, an epigenetic mode of action. In Vesugen's case, the research literature explores effects on genes tied to vascular cell function and endothelial maintenance, offering a proposed account of how a compact tripeptide could produce measurable vascular effects.
Across Khavinson-era preclinical work, Vesugen has been examined for support of the vascular wall and endothelial cells, regulation of vascular tissue in aging models, and geroprotective (anti-aging) endpoints framed around cardiovascular decline. It is one of the tissue-specific reference compounds cited when researchers discuss the short-peptide bioregulator hypothesis.
One compound, one line to read. The certificate on this page is run on the lot in the vial: an HPLC purity figure for Vesugen, with the chromatogram behind it. Read the purity line, then check the lot number against the label.
Every lot is tested before it is listed, and the certificate is replaced when a new lot goes on the shelf.
One compact tripeptide studied across vascular, genomic, and geroprotective research lines.
What's in the Vial
One lyophilized vial containing 20mg of Vesugen (Lys-Glu-Asp tripeptide), with no blend and no additional compounds. Tested for purity by third-party HPLC analysis. COA available on this product page.
- A single, well-defined tripeptide, not a blend, for clean study design
- The vascular-designated member of the Khavinson bioregulator family
- Primary research base in the vascular wall and endothelial function
- Studied for an epigenetic, gene-expression mode of action rather than surface signaling
- Explored for geroprotective endpoints framed around cardiovascular aging
- Compact Lys-Glu-Asp sequence, a reference compound for the bioregulator hypothesis
- 20mg of a single, well-defined compound per vial
About the Name
"Vesugen" is the original research designation given to the Lys-Glu-Asp tripeptide by the St. Petersburg group that developed it. The name traces directly back to the primary literature, where Vesugen appears alongside sibling bioregulators such as Vilon, Epithalon, and Thymogen, each assigned to a different target tissue. Using the original name keeps a researcher's references aligned with the published body of work rather than introducing a new label.
Research Context
Vesugen emerged from the short peptide bioregulator research program led by Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. The literature is concentrated in vascular biology and gerontology and is predominantly preclinical, with a substantial share originating from the founding research group itself. Vesugen is not approved by the FDA for human use, and independent replication outside the original research lineage remains limited. Researchers working with Vesugen are engaging a compound with a defined sequence and a specific but still-maturing evidence base.
Stacking Notes
Within the bioregulator research literature, Vesugen is most often discussed alongside its tissue-specific siblings, Vilon (immune), Epithalon (pineal), and Thymogen (Glu-Trp), reflecting the framework the class was built around. Researchers exploring the short-peptide hypothesis frequently reference these compounds together to compare mode of action across different target tissues. No published data exists on Vesugen combined with modern synthetic peptides outside this bioregulator family.
Storage
Store the lyophilized product refrigerated and away from light. Keep sealed and protected from moisture until use. Do not freeze.
- 20mg Vesugen (Lys-Glu-Asp tripeptide) per vial
- Single-peptide bioregulator, no blend
- Lys-Glu-Asp · L-lysyl-L-glutamyl-L-aspartic acid sequence
- Khavinson short-peptide research lineage
- Vascular-designated bioregulator
- Proposed epigenetic, gene-expression mechanism
- Single-vial, single-compound format
- Third-party HPLC tested
- COA available on product page
- Lyophilized for shelf stability
